Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
2 ASX healthcare shares set to explode 70% in 2022: expert
Here’s why the Immutep (ASX:IMM) share price is up today
Immutep (ASX:IMM) share price slips amid trial safety update
Share Market News
Why Afterpay, Immutep, Pushpay, and Vulcan shares are falling
Immutep (ASX:IMM) share price slides 20% despite latest trial results
Here’s why the Immutep (ASX:IMM) share price is rising on Tuesday
Immutep (ASX:IMM) share price hikes amid clinical trial momentum in FY21
The Immutep (ASX:IMM) share price is up 25% in a month and could go higher
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Immutep Ltd is a biotechnology company headquartered in Australia that focuses on personalised bio-therapeutic products for cancer.
|04 Jul 2022||$0.32||$0.01||3.23%||931,032||$0.32||$0.32||$0.31|
|01 Jul 2022||$0.31||$0.02||6.90%||1,009,919||$0.29||$0.31||$0.29|
|30 Jun 2022||$0.29||$-0.01||-3.39%||946,604||$0.31||$0.31||$0.29|
|29 Jun 2022||$0.30||$-0.03||-9.38%||1,698,513||$0.30||$0.31||$0.29|
|28 Jun 2022||$0.32||$0.01||3.23%||1,457,918||$0.32||$0.33||$0.31|
|27 Jun 2022||$0.31||$-0.01||-3.13%||1,372,115||$0.32||$0.33||$0.31|
|24 Jun 2022||$0.32||$0.02||6.67%||1,256,993||$0.30||$0.32||$0.29|
|23 Jun 2022||$0.30||$-0.02||-6.35%||1,088,876||$0.32||$0.32||$0.30|
|22 Jun 2022||$0.32||$-0.01||-3.08%||2,469,934||$0.33||$0.33||$0.30|
|21 Jun 2022||$0.33||$0.02||6.45%||1,272,456||$0.31||$0.33||$0.31|
|20 Jun 2022||$0.31||$0.00||0.00%||1,941,813||$0.30||$0.31||$0.30|
|17 Jun 2022||$0.31||$-0.01||-3.17%||1,124,293||$0.31||$0.31||$0.30|
|16 Jun 2022||$0.32||$-0.01||-3.08%||1,382,894||$0.33||$0.34||$0.32|
|15 Jun 2022||$0.33||$-0.02||-5.88%||3,208,203||$0.33||$0.33||$0.32|
|14 Jun 2022||$0.34||$-0.03||-8.11%||2,651,641||$0.34||$0.35||$0.33|
|10 Jun 2022||$0.37||$0.01||2.74%||730,838||$0.37||$0.38||$0.37|
|09 Jun 2022||$0.37||$-0.01||-2.70%||484,041||$0.37||$0.38||$0.37|
|08 Jun 2022||$0.37||$0.01||2.78%||1,023,274||$0.37||$0.38||$0.36|
|07 Jun 2022||$0.36||$-0.05||-12.35%||3,021,531||$0.39||$0.39||$0.36|
|01 Dec 2021||Russell Howard||Exercise||250||$118,750|| |
Conversion of securities.
|01 Dec 2021||Russell Howard||Issued||339||$161,319|| |
Issue of securities. 339,621 - Director Performance Rights
|01 Dec 2021||Russell Howard||Buy||250||$118,750|| |
Conversion of securities.
|01 Dec 2021||Marc Voigt||Issued||3||$1,710,000|| |
Issue of securities. 6,000,000 - Performance Rights
|04 Oct 2021||Grant Chamberlain||Buy||450||$240,750|| |
Conversion of securities.
|04 Oct 2021||Grant Chamberlain||Exercise||450||$240,750|| |
Conversion of securities. 900,000 - Performance Rights
|04 Oct 2021||Pete Meyers||Exercise||500||$267,500|| |
Conversion of securities. 1,000,000 - Performance Rights
|04 Oct 2021||Pete Meyers||Buy||500||$267,500|| |
Conversion of securities.
|Ms Lucinda (Lucy) Turnbull||Non-Executive Director||Feb 2022|| |
Ms Turnbull has previously served as Chairman from 06 October 2010 to 17 November 2017 of Immutep Limited. Ms Turnbull is an Australian businesswoman, philanthropist and former local government politician. With a background in commercial law and investment banking, she was the first female Lord Mayor of the City of Sydney from 2003 to 2004 and has served on the boards of the NSW Cancer Institute, the Sydney Children's Hospital Foundation, the Sydney Cancer Centre and the Sydney Festival. From 2015 to 2020 she served as the inaugural Chief Commissioner of the Greater Sydney Commission, a NSW state government body focused on delivering strategic planning for the whole of metropolitan Sydney.
|Dr Russell J Howard||Non-Executive ChairmanNon-Executive Director||May 2013|| |
Dr Howard is an Australian scientist, executive manager, and entrepreneur. He was a pioneer in molecular parasitology and commercialisation of DNA Shuffling. He is an inventor of 9 patents and has over 140 scientific publications. After his PhD in biochemistry from the University of Melbourne, he held positions at several research laboratories, including the National Institutes of Health in the USA where he gained tenure. In industry, Dr Howard worked at Schering Plough's DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and co-founder and CEO of Maxygen, Inc. After its spin out from GlaxoWellcome, as Maxygen's CEO, Dr. Howard led its IPO on NASDAQ and a secondary offering, raising US$ 260 million. Maxygen developed and partnered dozens of technology applications and products over 12 years of his tenure as CEO. After leaving Maxygen in 2008, he started the Cleantech company NovoNutrients Inc. (formerly Oakbio, Inc.) and remains involved in several innovative companies in the USA and Australia. He is currently Executive Chairman of NeuClone Pty Ltd.
|Mr Pete A Meyers||Non-Executive Deputy ChairmanNon-Executive Director||Feb 2014|| |
Mr Meyers is the Chief Financial Officer of Slayback Pharma LLC. Prior to joining Slayback, Mr Meyers served in Chief Financial Officer roles at Eagle Pharmaceuticals, Inc., Motif BioSciences Inc. and TetraLogic Pharmaceuticals Corporation. Prior to his role at TetraLogic, Mr Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read &Co., Credit Suisse First Boston LLC and, most recently, as CoHead of Global Health Care Investment Banking at Deutsche Bank Securities Inc. Mr Meyers is the Chairman and President of The Thomas M. Brennan Memorial Foundation, Inc., and serves on the Board of Directors of East End Hospice, Inc.
|Mr Marc Voigt||Chief Financial OfficerChief Executive OfficerExecutive Director||May 2012|| |
Mr Voigt has more than 21 years of experience in the financial and biotech industry, having joined the Immutep team in 2011 as the General Manager, European Operations based in Berlin, Germany. In May 2012, he became Immutep 's Chief Business Officer and in November 2012 its Chief Financial Officer, as well as continuing to focus on its European operations. Having started his career at the Allianz Group working in pension insurances and funds, he moved to net.IPO AG, a publicly listed boutique investment bank in Frankfurt where he was focused on IPOs and venture capital investments. He then worked for a number of years as an investment manager for a midsize venture capital fund based in Berlin, specialising in healthcare. He also gained considerable operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectfully, where he handled several successful licensing transactions and financing rounds. Since 2001, he has been a judge and coach in BPW, Germany's largest regional start-up initiative.
|Ms Deanne Miller||Chief Operating OfficerCompany SecretaryGeneral Counsel|| |
|Ms Indira Naidu||Joint Company Secretary||Jan 2021|| |
|Deanne Miller||Chief Operating OfficerCompany SecretaryGeneral Counsel|| |
|Dr Frederic Triebel||Chief Scientific Officer & Chief Medical Officer|| |
|Indira Naidu||Joint Company Secretary|| |
|HSBC Custody Nominees (Australia) Limited||324,272,007||38.11%|
|National Nominees Limited||60,483,220||7.11%|
|Citicorp Nominees Pty Limited||43,042,850||5.06%|
|J P Morgan Nominees Australia Pty Limited||31,044,298||3.65%|
|Cs Third Nominees Pty Limited <HSBC Cust Nom Au Ltd 13 A/C>||20,082,579||2.36%|
|BNP Paribas Noms Pty Ltd <DRP>||13,932,786||1.64%|
|HSBC Custody Nominees (Australia) Limited A/C 2||9,678,956||1.14%|
|UBS Nominees Pty Ltd||7,199,156||0.85%|
|BNP Paribas Nominees Pty Ltd Acf Clearstream||6,235,332||0.73%|
|Sandhurst Trustees Ltd <Endeavor Asset Mgmt Mda A/C>||5,499,923||0.65%|
|Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp>||4,501,767||0.53%|
|Brispot Nominees Pty Ltd <House Head Nominee A/C>||4,456,012||0.52%|
|Macenrock Pty Ltd <Macenrock S/F A/C>||3,622,897||0.43%|
|Ms Lucy Turnbull||2,981,626||0.35%|
|M & Hc Pty Ltd <Caudle Investment A/C>||2,314,372||0.27%|
|Mr Thomas Tscherepko||2,300,000||0.27%|
|Mr David Stewart Field||2,270,000||0.27%|